Targeting NCL in cancer cells using the anti-NCL aptamer AS1411 has been reported in brain and peripheral tumors (46–48), whereas AS1411-mediated targeting of NCL in ECs of the pathological vasculature in the retina resulted in reduced angiogenicity (49, 50). This evidence concerns the gene NUCLEOLIN and cancer.